Comparison of Atorvastatin and Fenofibrate in Dyslipidemia

ABSTRACT

Background: Abnormalities in plasma lipoproteins and deranged lipid metabolism rank as most firmly established and best understood risk factor for atherosclerosis Lipid regulating drugs, may be prescribed if, dietary therapy and lifestyle modification fails to adequately normalize blood lipid levels. The European / Atherosclerosis Society and National Cholesterol Education Programme (NCEP) consider fibric acid derivatives (Fibrates) and Hydroxy Methylglutaryl CoA reductase inhibitors (HMG CoA reductase inhibitors) to be effective therapy for combined dyslipidernia . The aim of present study was to compare the efficacy of Atorvastatin and Fenofibrate on various aspects of lipid profile viz. total cholesterol, serum LDL-C, serum VLDL, serum HDL-C and serum triglycerides in Indian patients having dyslipidemia. Methods: This study was conducted on 100 patients with abnormal lipid profile attending the OPD/Wards of Department of Medicine, Guru Nanak Dev Hospital, attached to Government Medical College, Amritsar. Results: The patients were randomly divided into 2 groups of 50 each, group A and B. Group A were put on Atorvastatin 10-20 mg daily and Group B were put on micronized Fenofibrate 200mg daily. Conclusion: The study concluded that none of these drugs were independently able to achieve NCEP ATP III goals. Atorvastatin has main effect or total serum cholesterol and LDL-C whereas Fenofibrate has main effect on serum triglycerides, VLDL-C and HDL-C .Combination of these may be tried to achieve the desired goal.